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Abstract 
Background: Double diabetes (DD) describes both individuals with obesity upon diagnosis of type 1 diabetes and 
those who have gained weight during follow-up, although cardiovascular risk factors (CVRF) are not well understood 
in this group. We aim to evaluate the frequency of DD in a real-world type 1 diabetes sample and the interaction of 
insulin treatment with CVRF.
Methods: Multicentre cross-sectional study of 2711 individuals with clinical diagnosis of type 1 diabetes from sec-
ondary diabetes centres in 20 Brazilian cities.
Results: Patients with diabetes duration <5 and ≥5 years had similar frequency of overweight (20.4 vs. 25 %) and 
obesity, (9.8 vs. 6.1 %), p 0.28 for trend. Insulin dose (U/kg/day) was lower in obese individuals compared to nor-
mal BMI, with mean (95 % CI) 0.72 (0.62–0.83) vs. 0.88 (0.84–0.92) U/kg/day for diabetes duration <5 years and 0.84 
(0.77–0.92) vs. 0.99 (0.97–1.01) U/kg/day for duration ≥5 years. Obese individuals had lower HDL (47.5 vs. 54.4 mg/dL) 
and higher non-HDL-cholesterol (134.5 vs. 115.2 mg/dL) than lean ones only among those with more than 5 years of 
diabetes.
Conclusions: Lower insulin doses in obese individuals point to a role of clinical heterogeneity in insulin deficiency 
rather than normal progression of type 1 diabetes. Early obesity in type 1 diabetes is associated to lower HDL-choles-
terol and higher number of CVRF. These data suggest a broad landscape of pathophysiological phenomena in double 
diabetes, rather than simple progression of a homogeneous clinical entity.
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Background
Type 1 diabetes is caused by autoimmune destruction 
of beta-cells, leading to absolute insulin deficiency dur-
ing its natural history. For this reason, type 1 diabetes 
has been associated, until almost a decade ago, with a 
leaner phenotype and absence of other cardiovascular 
risk factors upon diagnosis [1]. However, obesity is often 
recognised in individuals with type 1 diabetes already at 
diagnosis, owing partly to its rising incidence in the gen-
eral population. Not only is obesity compatible with a 
type 1 diabetes diagnosis, but it is also potentially a risk 
factor for its development [2].
Double-diabetes (DD) was a term coined to describe 
individuals with type 1 diabetes showing clinical features 
compatible with type 2 diabetes [3]. It has been vari-
ably used in literature, to describe both individuals with 
obesity and other insulin resistance (IR) characteristics 
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since diagnosis and those who have gained weight during 
follow-up, becoming obese over time [4]. Definition of 
a strict intermediate subtype between both types of dia-
betes is difficult, therefore this grey zone between them 
behaves more like a continuum according to current evi-
dence [1].
Insulin treatment mimics endogenous insulin secre-
tion imperfectly, thereby exposing individuals with type 
1 diabetes to a hyperinsulinaemic environment. This can 
contribute to weight gain and development of clinical fea-
tures associated with IR. Insulin dose, in this case, could 
be regarded as a surrogate marker of this hyperinsulinae-
mic environment, analogously to plasma insulin in non-
diabetic individuals with the metabolic syndrome [5].
However, the relationship between this hyperinsuli-
naemic environment and metabolic factors in a milieu 
without primary IR is still in discussion. The various 
DCCT/EDIC studies constitute an invaluable source of 
knowledge about the progression of obesity and cardio-
vascular risk factors in type 1 diabetes. Nevertheless, by 
the time the DCCT began recruitment, BMI was con-
sidered a tool for the clinical distinction between type 
1 and type 2 diabetes, leading obese patients (i.e., those 
above 130  % of ideal body weight) to be excluded from 
the trial [6]. Therefore, this sample is possibly not repre-
sentative of real-life type 1 diabetes today [7]. In UKPDS, 
likewise, individuals were considered to have type 2 dia-
betes solely based on age, milder hyperglycaemia, and 
absence of ketonuria [8]. However, distinction between 
type 1 and type 2 diabetes is not always straight forward. 
Up to 15 % of newly diagnosed individuals cannot have a 
diabetes type properly assigned [9, 10]. Therefore, differ-
ences between these two major subtypes of diabetes are 
becoming hazy [1], leading even to proposals of declas-
sifying the disease [11].
Cardiovascular risk factors such as dyslipidaemia and 
hypertension can be associated with type 1 diabetes. The 
interaction of intensive insulin treatment with them is 
not well understood, since intensive therapy can at the 
same time diminish cardiovascular risk (through better 
metabolic control) and worsen these factors via weight 
gain [2]. Thus, this complex interplay must be further elu-
cidated. Adequate understanding of these mechanisms 
could possibly lead to better therapeutic approaches.
This study aims to: (1) verify the frequency of over-
weight and obesity in a real-world sample of Brazilian 
individuals with type 1 diabetes; (2) evaluate the associa-
tion of insulin treatment with IR traits and cardiovascu-
lar risk factors.
Methods
An initial sample of 3591 individuals with type 1 diabe-
tes from the Brazilian Type 1 Diabetes Study Group was 
studied cross-sectionally. Patients have been recruited 
in 28 secondary and tertiary diabetes centres, located in 
20 cities in all five major geographic regions of Brazil. 
Recruitment period was from December 2008 to 2012. 
Inclusion criteria were a clinical diagnosis of type 1 dia-
betes, i.e., typical clinical symptoms (polydipsia, polyu-
ria and varying degrees of weight loss), insulin therapy 
requirement since diagnosis without interruption, and 
being followed at the diabetes center by at least 6 months 
prior to recruitment. Data were collected from medi-
cal records by a standardised medical chart review form 
[12]. After exclusion of 880 individuals by various crite-
ria (described on the flowchart depicted in Fig. 1), a final 
sample of 2711 individuals was studied.
The following variables have been recorded: gender, age 
at recruitment, diabetes duration, total insulin dose, insu-
lin dose per body weight, bolus/total insulin dose ratio, 
number of insulin applications (the sum of all basal and 
prandial insulin applications, used to characterise insu-
lin regimen), BMI, body surface area (calculated by the 
DuBois equation), systolic blood pressure (SBP), diastolic 
blood pressure (DBP). Mean blood pressure (MBP) was 
calculated as [SBP  +  2  ×  DBP]/3. Fasting plasma glu-
cose (FPG), HbA1c, total cholesterol, HDL-cholesterol, 
and triglycerides were dosed by previously described 
methods at each center (12). LDL-cholesterol was cal-
culated by Friedwald’s equation. Non-HDL-cholesterol 
was calculated as total cholesterol minus HDL. Familial 
history of type 2 diabetes in first-degree relatives, pres-
ence of overt nephropathy (defined as AER >30 mg/24 h, 
renal failure, dialysis treatment, or renal transplantation), 
coronary events (myocardial infarction, coronary bypass, 
3591 individuals with a clinical diagnosis 
of type 1 diabetes: 
-polydipsia 
-polyuria 
-variable degrees of weight loss 
-insulin use right from diagnosis 
-follow-up for at least 6 months on insulin
3097 individuals
2897 individuals
2711 studied 
individuals
494 individuals with 
A1C results in non-
NGSP traceable 
methods excluded 
200 individuals 
taking metformin 
excluded 
186 underweight 
individuals excluded 
(to avoid bias 
caused by acute 
decompensation)
Fig. 1 Flowchart of initial sample, excluded patients and final num-
ber of studied individuals
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or transluminal angioplasty) and number of cardiovas-
cular risk factors (low HDL, high LDL, hypertriglyc-
eridaemia, arterial hypertension) were also studied. Low 
HDL was defined as HDL-cholesterol below 50 mg/dL in 
women and 40 mg/dL in men. High LDL was defined as 
LDL-cholesterol above 100  mg/dL. Hypertriglyceridae-
mia was defined as triglycerides above 150 mg/dL. Arte-
rial hypertension was defined as blood pressure above 
140 × 90 mmHg in adults and above the 95th percentile 
for age and stature in children and adolescents or medi-
cal record reporting the diagnosis. Use of antihyperten-
sive medication was not used as criterion in order not to 
overestimate the number of patients with hypertension 
by including normotensive individuals using medication 
only for renal protection.
Individuals have been divided into three groups accord-
ing to BMI status: normal (BMI < 25 kg/m2 in adults or 
below the 85th percentile for those younger than 18); 
overweight (BMI between 25 and 29.9 kg/m2 for age ≥18 
or between percentiles 85 and 94.9 for age <18); obesity 
(BMI ≥ 30 kg/m2 or percentile ≥95). Patients were also 
divided in two groups according to diabetes duration: 
≥5  years and <5  years. There is evidence of significant 
weight gain in type 1 diabetes after approximately 5 years 
of diabetes duration in literature. This cut point also 
minimises the impact of recovering weight lost during 
acute decompensation [13, 14]. Moreover, five years can 
be regarded as an upper time limit for significant residual 
beta-cell function [15].
Frequencies of normal weight, overweight, and obese 
individuals have been compared between both diabetes 
duration subgroups by Mantel–Haenszel test and p value 
for linear-by-linear association was calculated.
After splitting the sample in six groups according to 
BMI status and diabetes duration, continuous variables 
have been transformed into square root, log, or inverse 
according to skewness of distribution. Insulin dose 
per body weight, total number of insulin applications, 
HbA1c, HDL-cholesterol, non-HDL-cholesterol, and 
MBP were separately entered as dependent variables in 
factorial ANCOVA models. The two lipid variables and 
MBP were chosen in order to illustrate the cardiovas-
cular risk factor profile while avoiding multicollinearity 
among correlated variables. BMI status, diabetes dura-
tion, familial history of type 2 diabetes, and gender have 
been entered as fixed factors. Continuous variables above 
have been entered as covariates for each other. Age and 
body surface area have also been entered as covariates, 
to minimise possible bias caused by the difference of age 
between diabetes duration groups, as well as in the inter-
pretation of insulin doses per body weight.
Missing data have been excluded list-wise. Post-hoc 
power analyses have been performed in the ANCOVA 
models. Type IV sum of squares was used for significance 
testing due to unequal group size. Partial eta-squared 
(η2), denoting percentage of total variance in the depend-
ent variable accounted for by the independent variable, 
p values, and power were recorded. Only findings with 
power above 80 % have been reported. An alpha level of 
5 % was considered significant.
Statistical analyses have ben conducted using SPSS 13.0 
Statistical Package (SPSS Inc., Chicago, IL). The study has 
been previously approved by each centre’s Research Eth-
ics Committee, as previously described [12].
Results
Clinical and laboratory features of individuals are 
depicted in Table  1. Frequencies of normal BMI, over-
weight, and obesity were similar in individuals with dia-
betes duration below and above or equal to 5  years. In 
individuals with less than 5 years of diabetes, 69.8 % had 
normal BMI, 20.4  % were overweight, and 9.8  % were 
obese. In those with 5 or more years of diabetes duration, 
68.9 % had normal BMI, 25 % were overweight, and 6.1 % 
were obese. Linear-by-linear association between BMI 
status and diabetes duration was not significant, with 
p = 0.278 (Fig. 2).
Insulin dose per body weight was significantly associ-
ated with age (partial-η2 0.039), HbA1c (partial-η2 0.054), 
HDL-cholesterol (partial-η2 0.012), number of insulin 
applications (partial-η2 0.073), BMI status (partial-η2 
0.008), and gender (partial-η2  <0.001). In the overall 
model, partial-η2 was 0.248, with p  <  0.001. Estimated 
marginal means were lower in obese individuals than in 
those with normal BMI, in both genders and regardless 
of diabetes duration, as depicted on Fig.  3a, b (numeric 
values described in Additional file 1: Table S1).
Number of insulin applications was associated with 
HbA1c (partial-η2 0.010), BSA (partial-η2 < 0.001), insu-
lin dose per kg of body weight (partial-η2 0.078), gender 
(partial-η2 0.004). Partial-η2 for the overall model was 
0.121 (p < 0.001). Estimated marginal means were similar, 
regardless of gender, BMI status and diabetes duration 
(depicted on Fig. 3c, d and Additional file 1: Table S1).
HbA1c was associated with age (partial-η2 0.012), 
HDL-cholesterol (partial-η2 0.010), non-HDL-cholesterol 
(partial-η2 0.053), mean blood pressure (partial-η2 0.005), 
body surface area (partial-η2 0.007), insulin dose (U/kg 
of body weight/day) (partial-η2 0.053), number of insu-
lin applications (partial-η2 0.009), BMI (partial-η2 0.008), 
and familial history of type 2 diabetes (partial-η2 0.005). 
Partial-η2 for the overall model was 0.163 (p  <  0.001, 
power 100  %). Significant interaction was seen between 
diabetes duration and familial history of type 2 diabetes 
(partial-η2 0.006, p = 0.005, power 84.3 %), and between 
BMI and diabetes duration (partial-η2 0.007, p =  0.002, 
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power 88.7  %). Estimated marginal means are depicted 
on Fig. 3e, f and Additional file 1: Table S1.
HDL-cholesterol was associated with age (partial-η2 
0.009), non-HDL-cholesterol (partial-η2 0.008), insu-
lin dose per body weight (partial-η2 0.013), and HbA1c 
(partial-η2 0.010). Partial-η2 for the overall model was 
0.079 (p < 0.001). Estimated marginal means are depicted 
on Fig. 4a, b and Additional file 1: Table S1.
Non-HDL-cholesterol was associated with age 
(partial-η2 0.007, body surface (partial-η2 0.005), HbA1c 
(partial-η2 0.051), HDL (partial-η2 0.009). Partial-η2 was 
0.121 for the overall model (p  <  0.001, power 100  %). 
Table 1 Clinical and laboratory features of studied individuals according to diabetes duration and BMI status (univariate 
analysis)
Values are expressed in mean (SD), except where noted
NS not significant
* p for linear-by-linear association (Mantel–Haenszel test)
a  multiply by 18.018 to convert to mg/dL
b  multiply by 38.61 to convert to mg/dL
c  multiply by 88.5 to convert to mg/dL
d  median [interquartile range]
Diabetes duration <5 years p Diabetes duration ≥5 years p
Normal Overweight Obesity Normal Overweight Obesity
n 601 176 84 1275 462 113
Female gender (%) 54.4 56.3 50 NS 55.5 59.3 67.3 0.01*
Age (years) 13.5 (6.6) 13.1 (8.0) 9.8 (6.6) <0.001 24.2 (11.5) 26.3 (12) 25.6 (13.9) 0.003
Diabetes duration 
(years)
2.32 (1.27) 2.20 (1.27) 2.20 (1.30) NS 12.9 (7.4) 14.1 (8) 13.9 (9.3) NS
Total insulin dose (U) 39.1 (21.8) 38.3 (21.0) 36.6 (23.7) NS 51.7 (21.3) 59.1 (21.2) 60.1 (25.1) <0.001
Insulin dose per body 
weight (U/kg)
0.90 (0.42) 0.82 (0.32) 0.83 (0.32) NS 0.95 (0.38) 0.88 (0.34) 0.81 (0.34) <0.001
Bolus/total insulin dose 
ratio (%)
22.6 (14.8) 21 (14.6) 20.8 (13) NS 21.8 (14.7) 23.4 (15.1) 24.3 (15.1) 0.049
Number of insulin doses 4.71 (1.19) 4.66 (1.27) 4.90 (1.23) NS 4.85 (1.20) 5.0 (1.20) 5.36 (1.17) <0.001
BMI (kg/m2) 18.7 (2.66) 21.4 (3.55) 23.4 (5.21) <0.001 21 (2.36) 25.5 (2.49) 29.5 (4.58) <0.001
Body surface area (m2) 1.33 (0.35) 1.36 (0.40) 1.23 (0.45) 0.03 1.57 (0.24) 1.72 (0.23) 1.77 (0.30) <0.001
Systolic blood pressure 
(mmHg)
101.6 (13.8) 102.7 (14.5) 103.1 (16.5) NS 113.1 (16.3) 117.7 (17.4) 117.6 (16.7) <0.001
Diastolic blood pressure 
(mmHg)
65.7 (10.4) 66.8 (11.7) 66.6 (9.7) NS 72.3 (11) 74.4 (11.1) 74.2 (11.7) 0.001
Fasting plasma glucose 
(mmol/L)a
9.6 (5.8) 9.6 (5.4) 9.8 (4.9) NS 10.1 (5.8) 10.2 (5.7) 9.9 (6.1) NS
HbA1c (%) 9.2 (2.5) 8.9 (2.2) 8.8 (2.4) NS 9.3 (2.3) 9.3 (2.3) 9.3 (2.3) NS
HbA1c (mmol/mol) 78 (27) 74 (25) 73 (26) NS 78 (25) 78 (25) 78 (25) NS
Total cholesterol 
(mmol/L)b
4.20 (1.02) 4.18 (0.81) 4.27 (0.87) NS 4.42 (1.05) 4.56 (1.14) 4.59 (1.23) 0.04
HDL-cholesterol 
(mmol/L)b
1.37 (0.37) 1.26 (0.30) 1.24 (0.27) 0.002 1.39 (0.39) 1.39 (0.41) 1.32 (0.34) NS
LDL-cholesterol 
(mmol/L)b
2.43 (0.80) 2.49 (0.66) 2.65 (0.76) NS 2.57 (0.85) 2.69 (0.87) 2.65 (0.86) NS
Non-HDL-cholesterol 
(mmol/L)b
2.84 (0.97) 2.90 (0.71) 3.08 (0.83) NS 3.02 (0.99) 3.17 (1.10) 3.26 (1.31) NS
Triglycerides (mmol/L)c, 
d
0.73 [0.52–1.05] 0.80 [0.58–1.04] 0.76 [0.57–1.24] NS 0.85 [0.61–1.14] 0.86 [0.64–1.29] 0.97 [0.68–1.46] 0.003
Familial history of type 2 
diabetes (%)
8.4 14.4 10.7 NS 14.3 22.7 24.1 <0.001*
Overt nephropathy (%) 0 0 0 NS 4.8 1.9 2.9 0.04
Coronary events (%) 0 0 0 NS 0.7 0.9 0.9 NS
Number of cardiovascu-
lar risk factors
0.90 (0.87) 0.95 (0.93) 1.01 (0.95) NS 0.93 (0.87) 1.28 (0.84) 1.30 (0.78) <0.001
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Significant interaction was seen between gender and 
familial history of type 2 diabetes (partial-η2 0.005, 
p = 0.002, power 85.9 %). Estimated marginal means are 
depicted on Fig. 4c, d and Additional file 1: Table S1.
Mean blood pressure showed partial-η2 0.304 for the 
overall model (p  <  0.001). Age (partial-η2 0.057), BSA 
(partial-η2 0.047), and HbA1c (partial-η2 0.005) were 
associated with MBP. Estimated marginal means are 
depicted on Fig. 4e, f and Additional file 1: Table S1.
Discussion
In this paper, we have studied a large sample of individuals 
with type 1 diabetes. About one third of this real-world 
sample was overweight/obese. Diabetes duration and 
intensity of insulin treatment were not related to weight 
excess. Insulin dose was inversely related to BMI status.
In univariate analysis, individuals with less than 5 years 
of diabetes duration were more obese, younger, and had 
lower HDL when compared to individuals with more 
than 5 years of diabetes duration. This finding could pos-
sibly be related to higher beta-cell residual function, since 
5 years of diabetes duration could be regarded as a maxi-
mum time limit for its presence in type 1 diabetes [15]. 
Although the findings of obesity and lower HDL could be 
related to genetic predisposition for IR, this group had a 
lower frequency of type 2 diabetes in family history. This 
finding is compatible with the lower age range in this 
group, since there might be not enough time for older 
generations in the families to manifest type 2 diabetes.
In the group with higher diabetes duration, obese 
individuals had lower insulin doses per body weight. 
Nephropathy could influence insulin doses by decreas-
ing its renal excretion. On the other hand, IR wouldn’t be 
higher in lean individuals (who had higher insulin doses) 
and our composite endpoint of nephropathy compre-
hends many individuals with mild or no renal disfunc-
tion. This lower insulin dose can be explained also by 
clinical inertia or fear of hypoglycaemia by both attend-
ing physicians and patients, since in this group HbA1c 
levels are far from recommended goals, although het-
erogeneity in the progression of beta-cell failure cannot 
be excluded given the findings of multivariable analysis. 
Longitudinal studies have previously demonstrated that 
C-peptide levels are higher at onset of type 1 diabetes in 
individuals with higher weight, although in a short term 
follow up of recently diagnosed patients [16].
Overweight and obesity were present in 31  % of our 
sample. Data about overweight and type 1 diabetes are 
very heterogeneous in literature, partly owing to dif-
ferent clinical criteria by which this clinical outcome is 
assessed. In a sample from Colorado, 16 % of youths with 
type 1 diabetes had BMIs above the 85th percentile for 
age (i.e., equivalent to both overweight and obese groups 
in our sample) upon diagnosis [17]. In 115 Spanish indi-
viduals with type 1 diabetes on intensive therapy, with a 
mean age of 12 years old and a mean diabetes duration of 
5 years, about 30 % were overweight and 20 % were obese 
[18]. In a sample of American youths from 0 to 17 years 
old with diabetes, 16.3 % were obese and were classified 
as obese-indeterminate diabetes. They had significantly 
older age of onset and frequency of hypertension than 
type 1 diabetes [19].
Data for adults are not as widely available, and fre-
quently analyzed jointly with data about children and 
adolescents. Both adolescents (mean age 15  years old) 
and adults (mean age 38  years old) gained weight after 
1 year of follow up in the DCCT [20]. In the completed 
trial, after 6.5 years of follow up, there was approximately 
13  % of adolescents in a sample with mean age around 
27 years old [14]. In the Wisconsin Epidemiologic Study 
of Diabetic Retinopathy (WESDR), in a group of patients 
diagnosed before age 30 and followed for 4 years, weight 
variation went from losing 0.6 to gaining 3.4  kg in dif-
ferent quartiles [13]. Besides age range, recruitment 
criteria highly influence these numbers. In DCCT, indi-
viduals with more than 130 % of ideal body weight were 
excluded, making obesity upon diagnosis virtually non-
existent in this sample and consequently in all follow-up 
studies [6].
As expected, insulin doses were higher in the group 
with longer disease duration, a finding compatible with 
the natural history of progressive insulin deficiency. Nev-
ertheless, they were lower in obese than in normal weight 
individuals. Age could be a source of bias, since groups 
divided by diabetes duration had different ages and there-
fore different ages at diagnosis. Age at diagnosis is known 
to influence progression of beta-cell failure [21], with 
individuals diagnosed after 18  years old having higher 
baseline residual beta-cell function and less pronounced 
decay after several years of follow-up, when compared 
Fig. 2 Relative frequencies of normal, overweight, and obese indi-
viduals, according to diabetes duration
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e f
Fig. 3 Estimated marginal means and 95 % CIs (according to BMI status) for insulin dose (a divided by diabetes duration; b divided by gender); total 
number of insulin applications (c divided by diabetes duration; d divided by gender); HbA1c (e divided by diabetes duration; f divided by gender). 
Significant differences (p < 0.05) are marked with asterisks
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Fig. 4 Estimated marginal means and 95 % CIs (according to BMI status) for HDL-cholesterol (a divided by diabetes duration; b divided by gender); 
non-HDL-cholesterol (c divided by diabetes duration; d divided by gender); mean blood pressure (e divided by diabetes duration; f divided by 
gender). Significant differences (p < 0.05) are marked with asterisks
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to individuals diagnosed in childhood. Since multivari-
able models have been corrected for body surface and 
age, this source of bias can be circumvented. Moreover, 
body surface was not significantly associated with insulin 
dose. Data from a Spanish group of individuals with type 
1 diabetes and aged on average 17 years old showed that 
insulin dose per body surface but not with dose per kg 
of body weight was higher in individuals with metabolic 
syndrome. No combined analysis of both parameters has 
been performed, though. Insulin dose was moderately 
correlated with HbA1c and BMI [22]. In the initial pilot 
of the DCCT, insulin dose per body weight was higher in 
adolescents (0.94 U/kg) than in adults (0.65 U/kg), sug-
gesting puberty-associated IR or clinical heterogeneity 
of late-onset type 1 diabetes rather than progression of 
beta-cell failure as an explanation for this variability [6]. 
Another possible hypothesis is that obesity could have 
different effects on insulin sensitivity in type 1 and type 
2 diabetes.
Interestingly, intensity of insulin treatment, as meas-
ured by total number of insulin applications, showed no 
difference either among different BMI strata or diabe-
tes duration subgroups. In spite of our cross-sectional 
design, this finding strongly suggests weight excess to 
be unrelated to intensity of insulin treatment. Moreo-
ver, owing to marked social and economic differences 
observed in our country which have been previously 
described [23], this sample has a particularly high num-
ber of individuals on conventional therapy (i.e., one or 
two insulin injections per day). This feature is especially 
suitable to assess the role of intense insulin therapy in 
this sample.
HbA1c didn’t show a clear trend of association with 
diabetes duration. This could be due to clinical hetero-
geneity or limitations of the cross-sectional design, since 
HbA1c is highly variable during follow-up, thus a single 
value could be misleading in this setting. The large vari-
ability in HbA1c levels could also be explained by factors 
related to residual pancreatic function and glucose/lipo-
toxicity, which were not directly evaluated in this study. 
There was a significant interaction between diabetes 
duration and familial history of type 2 diabetes, though, 
which could be related to clinical heterogeneity, partly 
explaining the irregular pattern of association between 
HbA1c and other variables. In literature, HbA1c was not 
correlated with BMI status in children and adolescents 
[18]. It showed no solid correlation with coronary artery 
disease (CAD), either [24].
Non-HDL-cholesterol was associated with weight 
excess in the predicted way. Obese individuals had 
higher non-HDL cholesterol than lean patients. Besides, 
interaction between gender and familial history of type 
2 diabetes suggests this relationship is probably due 
to hereditary traits related to IR. Weight gain has been 
hypothesised to trigger genetic factors related to IR [25]. 
In this aspect, our sample is different from literature in 
exhibiting worse HDL in obese individuals. In the DCCT, 
all metabolic parameters worsened following weight gain, 
except for HDL, which remained stable [4]. This differ-
ence could point to a contribution of individuals obese 
upon diagnosis for our results, since these have not been 
excluded from our series. Interestingly, there was no dif-
ference in obesity, lipids, and familial history of type 2 
diabetes in a substudy of DCCT/EDIC, when compar-
ing individuals with negative and positive islet antibodies 
[25]. Other studies have also assessed the difficulty of uti-
lising traditional clinical criteria to differentiate between 
type 2 diabetes and obese type 1 diabetes, with diabetic 
ketoacidosis being seen in 62  % of type 1 diabetes and 
40  % of type 2. Despite the significant statistical differ-
ence, accuracy is extremely low [19].
Obese Spanish children and adolescents with type 1 
diabetes had lower HDL and higher LDL than lean ones 
[18]. When assessing association of dyslipidaemia and 
CAD, individuals with type 1 diabetes and CAD had 
lower HDL and higher total cholesterol-to-HDL ratio 
than those without CAD [24]. Type 1 diabetes is classi-
cally associated with high HDL levels [2]. Nevertheless, 
obesity apparently is able to diminish this advantage [5]. 
Regarding risk of cardiovascular end points, the number 
of recorded CV events is too small to reach any valid con-
clusions in our sample. Besides, this analysis is beyond 
the scope of this study.
Blood pressure did not show a significant correlation 
with BMI in our sample. Hypertension has been previ-
ously shown to be more frequent in youths with type 2 
and obese with indeterminate diabetes type than in type 
1 diabetes [19]. Blood pressure is higher in individuals 
with type 1 diabetes with nephropathy or CAD than on 
complication-free subjects [24]. The presence of individ-
uals in all age ranges with a low frequency of CAD and 
clinical nephropathy in our sample could be a possible 
explanation for these differences.
Given the study design, data must be further investi-
gate in a prospective manner in order to confirm causal 
relationship among studied variables. External validity 
of the data must also be confirmed by studies from other 
populations, particularly in the adult age range, for which 
medical literature is still incipient in double diabetes.
Some limitations of the study should be addressed. 
The most important is the cross-sectional design. No 
causal relationship can be established with our data. 
Nevertheless, we feel the large sample and the fact 
patients have been unselected regarding BMI at diagno-
sis give a more realistic perspective of double diabetes in 
the heterogeneous scenario of type 1 diabetes. Another 
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limitation is the absence of pancreatic autoantibodies 
in the diagnosis of type 1 diabetes. Although they at 
first could potentially contribute to differential diagno-
sis between type 1 diabetes and other subtypes of dia-
betes, there was no difference between lean and obese 
subjects regarding islet antibodies in the DCCT-EDIC 
[25]. Besides, even utilising this diagnostic tool, differ-
ential diagnosis can be difficult in a significant propor-
tion of patients, as demonstrated in Finnish individuals 
[9, 10]. Moreover, although we hypothesised that clini-
cal variability of residual beta-cell function as an expla-
nation for the lower insulin dose in obese than in lean 
individuals, no direct measurements of C-peptide or 
other pancreatic function estimate were available in our 
sample. There is some evidence in literature showing 
residual beta-cell function to be higher in DD than in 
classical type 1 diabetes, though [26]. Furthermore, as 
seen by HbA1c levels far from the recommended goals, 
we can infer insulin treatment was not fully optimised 
in this sample. Nevertheless, multivariable models have 
been corrected for HbA1c, potentially tapering down 
the effects of metabolic decompensation on our main 
finding.
Conclusions
In summary, approximately 30 % of individuals with type 
1 diabetes are overweight in our population. The relation-
ship between overweight and cardiovascular risk factors 
is more evident in type 1 diabetes with disease duration 
greater than 5 years. These data suggest a role for meta-
bolic memory on this relationship also in type 1 diabetes, 
analogously to what is already known for type 2 diabetes. 
However, low HDL seems to be related to early obesity 
in type 1 diabetes and the metabolic environment associ-
ated to this condition. Weight excess was not specifically 
associated with intensity of insulin treatment and diabe-
tes duration in this large group of individuals with type 1 
diabetes. Obese individuals used lower insulin doses than 
lean ones, suggesting either suboptimal insulin treatment 
or clinical heterogeneity of type 1 diabetes, in which 
higher weight is possibly associated to higher residual 
beta-cell function. We can suggest that obesity associated 
to type 1 diabetes is multifactorial and occurs either upon 
diagnosis or in the first 5 years of disease. It is related to 
IR traits and occurs after this time period as a result of 
interaction between genetic background and hypergly-
caemic milieu. However, both conditions represent sub-
groups of type 1 diabetic individuals that will probably 
need an early follow-up and management of cardiovas-
cular risk factors. Concluding, these data suggest a broad 
landscape of clinical phenomena in the pathophysiology 
of DD, rather than simple progression of a homogeneous 
clinical entity.
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